Abstract Library

#4533 Receptor radionuclide therapy with 177Lu-DOTATOC (177Luedotreotide or 177Lu-octreotide) in SSTR positive patients: A multicentre, prospective, phase II trial

Introduction: For advanced G1-G2 GEP-NET patients, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE can be recommended. However, there are several SSTR-positive tumours for which PRRT has previously shown efficacy that are not currently covered by the indications for 177Lu-DOTATATE in Italy and, therefore, cannot benefit from it. Less used and studied is the 177Lu-DOTATOC. This is a radiopeptide with excellent safety and efficacy profile in PRRT and certainly not lower than 177Lu-DOTATATE.

Conference:

Presenting Author: Sansovini M

Authors: Sansovini M, Nicolini S, Grassi I, Marini I, Matteucci F,

Keywords: Lu-dotatoc, Radiopharaceutical Therapy Factory, SSTR positive tumour,

#3800 Correlation between early response and lesion dosimetry in patients with advanced neuroendocrine tumor (NET) treated with radioligand therapy (RLT)

Introduction: The identification of predictive parameters of response to radioligand therapy (RLT) in NET patients is essential in order to avoid futile therapy toxicities. The relation between the tumor absorbed dose and therapy response has so far not been established.

Conference:

Presenting Author: Durmo R

Authors: Durmo R, Fioroni F, Grassi E, Coruzzi C, Giulia B,

Keywords: RLT, Dosimetry,

#1507 The CDK4/6 Inhibitor Palbociclib Induces Anti-proliferative Mechanisms in Gastroenteropancreatic Neuroendocrine Neoplasms In Vitro

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with heterogeneous molecular backgrounds and mostly unknown druggable driver mutations. Especially for the midgut NENs effective treatment options are limited. The retinoblastoma pathway is often inactive due to CDK4/6 overexpression in pancreatic NENs. Palbociclib is a FDA approved (ER-positive and HER2-negative breast cancer) cyclin-dependent kinases 4 and 6 inhibitor and might impair cell cycle progression and proliferation.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Briest F

Authors: Briest F, Grass I, Siegmund B, Grabowski P,

Keywords: GEP-NEN, targeted therapy, cyclin-dependent kinases 4/6,

#1172 Dual Inhibition of PI3K and mTORC1/C2 by PKI-587 (PF-05212384) as a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease and Its Effect on AKT-Signaling

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are heterogeneous in their clinical behavior and therapeutic options are still not satisfactory. The “crosstalk” of different signaling pathways in NEN cells appears to be more complex as known already. PKI-587 is a highly potent novel dual inhibitor of PI3K and mTORC1/C2.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Freitag H, Briest F, Christen F, Grass I, Lewens F,

Keywords: dual inhibition, PI3K, mTOR, PKI-587,RAD001, signaling,